Team Type 1
 | Team Name: Team Type 1 Country: USA Team Website: www.teamtype1.org 2010 Roster: 17 riders Bikes Used: Colnago CX-1 Bicycles |
2009 Highlights
About Team Type 1Team Type 1 was created in 2004 by Phil Southerland and Joe Eldridge, a pair of avid cyclists with Type 1 diabetes. In 2006 and 2007, the pair captained Team Type 1 to back-to-back victories in the eight-person team division of the Race Across America (RAAM). In 2008, the team grew to include a 15-rider professional continental team that included four riders with Type 1 diabetes. In their inaugural pro season, Team Type 1 compiled 45 victories, including winning the team classification at the Tour de Beauce and the Vuelta Mexico and placing two riders (Glen Chadwick and Moises Aldape) in the Olympic road race in Beijing.In 2009, Team Type 1 expanded to include a triathlon team, a developmental squad, a women's professional squad and two teams for RAAM: Team Type 1 and Team Type 2. The Type 1 athletes in these programs strive to instill hope and inspiration for people around the world affected by diabetes. The team encourages control of diabetes through diet, exercise and the use of current technology. Team Roster
IMPORTANT SAFETY INFORMATION FOR LANTUS® (insulin glargine [rDNA origin] injection) Do not take Lantus® if you are allergic to insulin or any of the inactive ingredients in Lantus®. You must test your blood sugar levels while using insulin, such as Lantus®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision. Do NOT dilute or mix Lantus® with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. Lantus® must only be used if the solution is clear and colorless with no particles visible. Do not share needles, insulin pens or syringes with others. The most common side effect of insulin, including Lantus®, is low blood sugar (hypoglycemia), which may be serious. Other possible side effects may include injection site reactions, including changes in fat tissue at the injection site, and allergic reactions, including itching and rash. In rare cases, some allergic reactions may be life threatening. Tell your doctor about other medicines and supplements you are taking because they can change the way insulin works. Before starting Lantus®, tell your doctor about all your medical conditions including if you have liver or kidney problems, are pregnant or planning to become pregnant, or are breast-feeding or planning to breast-feed. Lantus® Indications and Usage Prescription Lantus® is a long-acting insulin used to treat adults with type 2 diabetes and adults and children (6 years and older) with type 1 diabetes for the control of high blood sugar. It should be taken once a day at the same time each day to lower blood glucose. Do not use Lantus® to treat diabetic ketoacidosis. Lantus® SoloSTAR® is a disposable prefilled insulin pen. Please see accompanying file for full prescribing information or visit www.Lantus.com. IMPORTANT SAFETY INFORMATION FOR APIDRA® (insulin glulisine [rDNA origin] injection) Do not use Apidra® during a low blood sugar reaction (hypoglycemia) or if you are allergic to any of the ingredients in Apidra®. You must test your blood sugar levels while using insulin, such as Apidra®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision. Apidra® must only be used if the solution is clear and colorless with no particles visible. Do not share needles, insulin pens or syringes with others. Apidra®, when given by injection under the skin, should not be mixed with insulins other than NPH. Do not mix Apidra® with any insulin when used in the pump or for intravenous administration. Insulin devices and needles must not be shared between patients. The most common side effect of insulin, including Apidra®, is low blood sugar (hypoglycemia), which may be serious. Other possible side effects may include low blood potassium, injection site reactions, such as changes in fat tissue at the injection site, and allergic reactions, such as itching and rash. Less common, but potentially more serious or lifethreatening, is generalized allergy to insulin, including anaphylactic reactions. Tell your doctor about other medicines and supplements you are taking because they can change the way insulin works. Before starting Apidra®, tell your doctor about all your medical conditions including if you have liver or kidney problems, are pregnant or planning to become pregnant, or are breast-feeding or planning to breast-feed. Apidra® Indications and Usage Prescription Apidra® is for adults with type 2 diabetes or adults and children (4 years and older) with type 1 diabetes to improve blood sugar control. Apidra® is usually used with a longer-acting insulin. When used as a mealtime insulin, Apidra® should be given within 15 minutes before or within 20 minutes after starting a meal. Apidra® SoloSTAR® is a disposable prefilled insulin pen. Please see accompanying file for full prescribing information or visit www.Apidra.com. IMPORTANT SAFETY INFORMATION FOR LANTUS® SoloSTAR® and APIDRA® SoloSTAR® Lantus® SoloSTAR® pen is grey and Apidra® SoloSTAR® pen is blue. Each contains a different type of insulin (long-acting vs. rapid-acting). Before using Lantus® SoloSTAR® or Apidra® SoloSTAR®, carefully examine the label on the pen to make sure you have the correct insulin. |
